SCHEMBL20600736

SCHEMBL20600736

Nc1cccc(-c2nc(N)c3nccn3c2-c2cc(F)c3ncccc3c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.46
ADORA3 P0DMS8 2/20 0.46
ADORA1 P30542 2/20 0.46
MAP4K4 O95819 2/20 0.42
PLK4 O00444 1/20 0.42
EGFR P00533 1/20 0.42
ROS1 P08922 1/20 0.42
PIM1 P11309 1/20 0.42
AXL P30530 1/20 0.42
FLT3 P36888 1/20 0.42
FRK P42685 1/20 0.42
MAP4K2 Q12851 1/20 0.42
NTRK3 Q16288 1/20 0.42
MINK1 Q8N4C8 1/20 0.42
AURKB Q96GD4 1/20 0.42
HIPK2 Q9H2X6 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
STK17A Q9UEE5 1/20 0.42
ALK Q9UM73 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20600432 0.92 ADORA2A (0.46) ADORA2AADORA3ADORA1MAP4K4GRIA1
SCHEMBL20600611 0.90 ADORA1 (0.44) ADORA2AADORA3ADORA1MAP4K4PLK4
SCHEMBL20600733 0.89 KLK7 (0.46) ADORA2AADORA3ADORA1GRIA1TNK2
SCHEMBL20600659 0.89 ADORA2A (0.45) ADORA2AADORA3ADORA1PIM1GRIA1
SCHEMBL20600461 0.88 GRIA1 (0.49) ADORA2AADORA3ADORA1GRIA1CCNA2
SCHEMBL20600468 0.87 ADORA2A (0.47) ADORA2AADORA3ADORA1PDE4D
SCHEMBL20600680 0.87 ADORA2A (0.43) ADORA2AADORA3ADORA1PIM1GRIA1
SCHEMBL20600510 0.86 ADORA2A (0.42) ADORA2AADORA3ADORA1PIM1GRIA1
SCHEMBL20600652 0.85 ADORA2A (0.43) ADORA2AADORA3ADORA1GRIA1KLK7
SCHEMBL20600505 0.84 KDM1A (0.44) ADORA2AADORA3ADORA1GRIA1TNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US claimed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP claimed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO claimed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.